O-GlcNAc




O-GlcNAcylation is a type of post-translational modification involving the addition of a single N-acetylglucosamine (GlcNAc) moiety to serine or threonine residues on nuclear and cytoplasmic proteins. This modification is dynamic and reversible, playing a crucial role in various cellular processes including signal transduction, protein stability, and gene expression. O-GlcNAcylation is catalyzed by the enzyme O-GlcNAc transferase (OGT), which transfers the GlcNAc from uridine diphosphate N-acetylglucosamine (UDP-GlcNAc) to target proteins. The removal of GlcNAc is carried out by O-GlcNAcase (OGA).
Function[edit]
O-GlcNAcylation impacts a wide range of cellular functions. It is involved in the regulation of transcription factors, modulation of cytoskeletal dynamics, and control of protein degradation. This modification is also implicated in the cellular stress response, where it acts as a nutrient sensor to regulate the cell's metabolic state. Additionally, O-GlcNAcylation plays a role in the regulation of cell cycle and apoptosis.
Regulation[edit]
The balance between O-GlcNAcylation and phosphorylation is critical for the proper functioning of many cellular processes. O-GlcNAcylation is often found to compete with phosphorylation at the same or adjacent sites on proteins, a phenomenon known as the O-GlcNAc/phosphorylation interplay. This interplay is crucial for the regulation of signal transduction pathways and the activity of various proteins.
Pathological Implications[edit]
Aberrant O-GlcNAcylation has been linked to the development of several diseases, including diabetes, Alzheimer's disease, and cancer. In diabetes, increased O-GlcNAcylation levels have been observed, which can interfere with insulin signaling and glucose metabolism. In Alzheimer's disease, abnormal O-GlcNAcylation of tau protein contributes to the formation of neurofibrillary tangles, a hallmark of the disease. In cancer, altered O-GlcNAcylation levels have been associated with tumor progression and metastasis.
Research and Clinical Implications[edit]
Understanding the role of O-GlcNAcylation in disease has led to the exploration of OGT and OGA as potential therapeutic targets. Inhibitors of these enzymes are being studied for their potential to modulate O-GlcNAcylation levels and treat diseases associated with its dysregulation.

This article is a biochemistry stub. You can help WikiMD by expanding it!
Ad. Transform your health with W8MD Weight Loss, Sleep & MedSpa

Tired of being overweight?
Special offer:
Budget GLP-1 weight loss medications
- Semaglutide starting from $29.99/week and up with insurance for visit of $59.99 and up per week self pay.
- Tirzepatide starting from $45.00/week and up (dose dependent) or $69.99/week and up self pay
✔ Same-week appointments, evenings & weekends
Learn more:
- GLP-1 weight loss clinic NYC
- W8MD's NYC medical weight loss
- W8MD Philadelphia GLP-1 shots
- Philadelphia GLP-1 injections
- Affordable GLP-1 shots NYC
|
WikiMD Medical Encyclopedia |
Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian